Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qizhijiangtang Capsule for early diabetic kidney disease with microalbuminuria
ChiCTR1900023390Phase 4Recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Jan 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of qizhijiangtang in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (4 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoint: Urinary microalbumin creatinine ratio. Started Jan 2019; status: recruiting.
02
Drugs
qizhijiangtang
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900023390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023390.